Peter Beyer

Peter Beyer

Auto-generated profile, based on publicly available information

Peter Beyer

Global Antibiotics Research and Development Partnership, Drugs for Neglected Diseases Initiative , Geneva , Switzerland

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2024 in Medical Mycology
Verified
Journal Article
Open access
PDF file
TMTina Marinelli
Tina Marinelli
HKHannah Yejin Kim
Hannah Yejin Kim
CHCatriona Halliday
Catriona Halliday
KGKatherine Garnham
Katherine Garnham
OBOlivia Bupha-Intr
Olivia Bupha-Intr
CMC Orla Morrissey
C Orla Morrissey
Recognizing the growing global burden of fungal infections, the World Health Organization established a process to develop a priority list of fungal pathogens (FPPL). In this systematic review, we aimed to evaluate the epidemiology and impact of infections caused by Fusarium spp., Scedosporium spp., and Lomentospora prolificans to inform the first FPPL. PubMed and Web of Sciences databases were searched to identify studies published between January 1, 2011 and February 23, 2021, reporting on mortality, complications and sequelae, antifungal susceptibility, preventability, annual incidence, and trends. Overall, 20, 11, and 9 articles were included for Fusarium spp., Scedosporium spp., and L. prolificans, respectively. Mortality rates were high in those with invasive fusariosis, scedosporiosis, and lomentosporiosis (42.9%–66.7%, 42.4%–46.9%, and 50.0%–71.4%, respectively). Antifungal susceptibility data, based on small isolate numbers, showed high minimum inhibitory concentrations (MIC)/minimum effective concentrations for most currently available antifungal agents. The median/mode MIC for itraconazole and isavuconazole were ≥16 mg/l for all three pathogens. Based on limited data, these fungi are emerging. Invasive fusariosis increased from 0.08 cases/100 000 admissions to 0.22 cases/100 000 admissions over the time periods of 2000–2009 and 2010–2015, respectively, and in lung transplant recipients, Scedosporium spp. and L. prolificans were only detected from 2014 onwards. Global surveillance to better delineate antifungal susceptibility, risk factors, sequelae, and outcomes is required.

27 June 2024 in Medical Mycology
Verified
Journal Article
Open access
PDF file
JCJulia E Clark
Julia E Clark
HKHannah Yejin Kim
Hannah Yejin Kim
WSWendy Laureijssen-van de Sande
Wendy Laureijssen-van de Sande
BMBrendan McMullan
Brendan McMullan
PVPaul Verweij
Paul Verweij
CMC Orla Morrissey
C Orla Morrissey
The World Health Organization, in response to the growing burden of fungal disease, established a process to develop a fungal priority pathogens list. This systematic review aimed to evaluate the epidemiology and impact of eumycetoma. PubMed and Web of Science were searched to identify studies published between 1 January 2011 and 19 February 2021. Studies reporting on mortality, inpatient care, complications and sequelae, antifungal susceptibility, risk factors, preventability, annual incidence, global distribution, and emergence during the study time frames were selected. Overall, 14 studies were eligible for inclusion. Morbidity was frequent with moderate to severe impairment of quality of life in 60.3%, amputation in up to 38.5%, and recurrent or long-term disease in 31.8%–73.5% of patients. Potential risk factors included male gender (56.6%–79.6%), younger age (11–30 years; 64%), and farming occupation (62.1%–69.7%). Mycetoma was predominantly reported in Sudan, particularly in central Sudan (37%–76.6% of cases). An annual incidence of 0.1/100 000 persons and 0.32/100 000 persons/decade was reported in the Philippines and Uganda, respectively. In Uganda, a decline in incidence from 3.37 to 0.32/100 000 persons between two consecutive 10-year periods (2000–2009 and 2010–2019) was detected. A community-based, multi-pronged prevention programme was associated with a reduction in amputation rates from 62.8% to 11.9%. With the pre-specified criteria, no studies of antifungal drug susceptibility, mortality, and hospital lengths of stay were identified. Future research should include larger cohort studies, greater drug susceptibility testing, and global surveillance to develop evidence-based treatment guidelines and to determine more accurately the incidence and trends over time.

31 March 2011 in Plasma Physics and Controlled Fusion
Verified
Journal Article
Closed access
PBP Beyer
P Beyer
FSF de Solminihac
F de Solminihac
MLM Leconte
M Leconte
XGX Garbet
X Garbet
FWF L Waelbroeck
F L Waelbroeck
SBS Benkadda
S Benkadda

28 July 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SPSarah Paulin
Sarah Paulin
RARichard A. Alm
Richard A. Alm
PBPeter Beyer
Peter Beyer
The clinical pipeline continues to be insufficient to contain antimicrobial resistance, and further investment and research is needed to ensure that a robust pipeline is built to treat the WHO priority pathogens list of antibiotic-resistant bacteria. To shed light further upstream on the preclinical pipeline the WHO has undertaken a review of the antibacterial preclinical pipeline and published the data of all identified projects in a publicly accessible database. The database captures 252 unique antibacterial agents in preclinical development being developed by 145 individual institutions, of which the majority are smaller biotech companies and academic institutions. There is a higher degree of innovation in the preclinical pipeline with a significant number of non-traditional approaches being pursued. For even a fraction of these projects to reach clinical development or the market, there is a need to shift the market dynamics for new antibacterials through the identification of new solutions beyond push and pull incentives.

19 January 2005 in Journal of Nuclear Materials
Verified
Journal Article
Closed access
CFC.F. Figarella
C.F. Figarella
PGPh. Ghendrih
Ph. Ghendrih
YSY. Sarazin
Y. Sarazin
GAG. Attuel
G. Attuel
SBS. Benkadda
S. Benkadda
VGV. Grandgirard
V. Grandgirard

1 January 2022
Verified
Book
Closed access
PBPeter Beyer
Peter Beyer
"Globalization/Glocalization: Developments in Theory and Application" published on 20 Jan 2022 by Brill.